Merck & Co., Inc. — Director's Dealing 2024

Mar 11, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Harpoon Therapeutics, Inc. (HARP)
CIK: 0001708493
Period of Report: 2024-03-11

Reporting Person: Merck & Co., Inc. (N/A)
Reporting Person: MERCK SHARP & DOHME LLC (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-03-11	Common Stock, par value $0.0001	P	21397205	$23.00	Acquired	1000	Indirect

Footnotes

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. ("Parent"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"), Merger Sub merged with and into Harpoon (the "Merger") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation.

F2: (Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares.